Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best performing ...

BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $11 from $10 and keeps an Underperform rating on the ...

Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

PNC Financial Services Group Inc. reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 15.2% in the fourth quarter, Holdings Channel.com reports. The institutional ...

In this article, we will see how TG Therapeutics, Inc. (NASDAQ:TGTX) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever ...

TG Therapeutics TGTX shares soared 10.2% in the last trading session to close at $40.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501 ...